Sign in | Register
Services
Solutions
About Us
Resources
Contact Us

Webinar - The Industrialization of In Vivo CAR-T Therapy Development

driving-the-industrialization.png

CAR-T therapies have revolutionized blood cancer treatment, but traditional ex vivo manufacturing remains costly and time-consuming. Next-generation in vivo CAR-T is set to change the game, driven by two delivery platforms: LVV (viral) and LNP (non-viral). Join our online webinar to explore how LVV and mRNA-tLNP are accelerating the industrialization of in vivo CAR-T therapies.

Chunling_Xuan.png
Chunling Xuan
Director, LVV PD, ProBio
Jiang_Xu.png
Jiang Xu
Head of LNP formulation, ProBio
Time
Topic
15:30-16:15
Lentiviral Vector Process Development for In Vivo CAR-T: Key Points and Core Challenges
Dr. Chunling Xuan, Director, LVV PD, ProBio
Insights into process development challenges.
Key considerations in quality control and consistency.
Regulatory expectations and technical strategies for compliance.
16:15-17:00
mRNA-tLNP for In Vivo CAR-T: Challenges and Solutions
Dr. Jiang Xu, Head of LNP formulation, ProBio
Practical experience in developing CMC processes for mRNA-tLNP.
Analytical method development and optimization.
Latest biological data and findings from experimental validation.